Carregando empresa
Keep exploring
The themes Edwards Lifesciences is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Medical Devices
Graded A or B and worth $2B or more: A first, then the largest.
MDTMedtronic plcUS$ 130BA+
SYKStryker Corp.US$ 121,3BA+
GEHCGE Healthcare Technologies Inc.US$ 37,4BA
GKOSGlaukos CorpUS$ 14,6BA
PENPenumbra, IncUS$ 12,7BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 de out. de 2026CBGraded C, now B
MCKMckesson Corporation4 de nov. de 2026BAGraded B, now A
CVSCVS Health Corp4 de nov. de 2026BAGraded B, now A
BIIBBiogen Inc.28 de out. de 2026BAGraded B, now A- GEHCGE Healthcare Technologies Inc.28 de out. de 2026CAGraded C, now A
Como ganha dinheiro
- Catheter-delivered aortic valve replacement72%
- Catheter-delivered mitral and tricuspid valve repair and replacement11%
- Surgical heart valve products16%
As participações na receita são estimativas para nine months ended September 30, 2026, não números de um relatório oficial.
Concorre com
O que vende5
SAPIEN
A family of tissue valves delivered through a catheter to replace a diseased aortic valve; some systems are also used for pulmonary valve replacement.
PASCAL
A catheter-delivered device that helps bring together the leaflets of a leaking mitral or tricuspid valve.
EVOQUE
A tissue valve delivered through a catheter to replace a leaking tricuspid valve.
Mostrar mais 2
SAPIEN M3
A tissue valve delivered through a catheter to replace a diseased mitral valve.
INSPIRIS RESILIA, KONECT RESILIA, and MITRIS RESILIA
Surgical tissue valve products for aortic and mitral valve replacement; KONECT is a tissue valve conduit used in complex combined procedures.
Quem compra3
- Hospitals and health systems buy devices directly from Edwards sales teams or through distributors; in the United States, sales are mainly direct.
- Hospital purchasing groups and healthcare networks negotiate supplier contracts on behalf of hospitals.
- Heart specialists, including cardiac surgeons and interventional cardiologists, use the devices and take part in choosing treatments.
Em que se apoia e o que pode quebrá-lo
Do que o negócio depende
- 1A large part of the business depends on hospitals adopting catheter-delivered aortic valve replacement and on clinicians choosing Edwards devices.
- 2Sales depend in part on government and private insurers covering procedures and paying hospitals enough to support their use.
- 3Some materials and components come from single-source suppliers; switching critical suppliers can require lengthy regulatory review.
- 4The company relies on clinical studies and regulatory clearances or approvals to bring devices to market and expand their permitted uses.
O que pode dar errado
- 1If clinical studies do not show the needed results, or regulators do not approve new devices or uses, Edwards may be unable to sell those products or expand their use.
- 2Manufacturing, quality, safety, or delivery problems at Edwards or its suppliers could interrupt access to implanted heart valves and other devices.
- 3If insurers or government health programs restrict coverage or reduce payments, hospitals may buy fewer devices or seek lower prices.
Demonstrações financeiras completas →
Sobre a Edwards Lifesciences Corporation
Edwards makes devices that replace or repair damaged heart valves. Some are delivered through a catheter, a thin tube passed through a blood vessel, while others are implanted during open-heart surgery. Hospitals and heart specialists use these devices to treat diseases affecting the aortic, mitral, and tricuspid valves.
- Sede
- Irvine, California, United States
- Fundada em
- 1958
- Funcionários
- Approximately 16,000 (December 31, 2025, medium)
- Listada em
- New York Stock Exchange
- Fim do exercício
- December 31
Construído a partir dos próprios documentos de Edwards Lifesciences Corporation entregues à Comissão de Valores Mobiliários dos EUA (SEC). Os números são os divulgados, com o histórico por ação recalculado para a base de ações de hoje. Isto descreve um negócio — não é recomendação de investimento nem sugestão de compra ou venda.
